Partnerships

Biologics

HUTCHMED SANOVO trial shows PFS gain for savolitinib plus osimertinib

HUTCHMED's Phase III SANOVO trial met its primary endpoint in treatment-naïve MET-overexpressing EGFR-mutated NSCLC, with an encouraging early overall survival signal.
HUTCHMED's Phase III SANOVO trial met its primary endpoint in treatment-naïve MET-overexpressing EGFR-mutated NSCLC, with an encouraging early overall survival signal.
The Biotech Times Editorial Team  · 
Biologics

Immuron posts record A$7.7m FY26 sales as CDI asset heads to partner

The Melbourne-based polyclonal antibody company reported 6% revenue growth and a A$1.4m profit improvement while advancing IMM-529 towards a Phase 2
The Melbourne-based polyclonal antibody company reported 6% revenue growth and a A$1.4m profit improvement while advancing IMM-529 towards a Phase 2
The Biotech Times Editorial Team  · 
Biologics

Leios Therapeutics licenses 10XB-101 to CMS for China market

Leios Therapeutics has signed an exclusive licensing deal with CMS subsidiaries covering mainland China, its second major regional deal this year.
Leios Therapeutics has signed an exclusive licensing deal with CMS subsidiaries covering mainland China, its second major regional deal this year.
The Biotech Times Editorial Team  · 
Biologics

Insulinova partners San Raffaele to test encapsulated beta cells

Insulinova will fund OSR-led research combining stem cell-derived beta cells with Austrianova's Cell-in-a-Box encapsulation platform to pursue immunosuppression-free
Insulinova will fund OSR-led research combining stem cell-derived beta cells with Austrianova's Cell-in-a-Box encapsulation platform to pursue immunosuppression-free
The Biotech Times Editorial Team  · 

Catheter Precision lands Cardinal Health deal and Johns Hopkins order

The cardiac electrophysiology device maker also placed its first VIVO 3D imaging system in Germany, marking a step into one of Europe's largest EP
The cardiac electrophysiology device maker also placed its first VIVO 3D imaging system in Germany, marking a step into one of Europe's largest EP
The Biotech Times Editorial Team  · 
Bioprocessing

PharmAla secures MDMA patent and hires Canaccord as banking partner

PharmAla Biotech has been granted a US process patent for enantioselective MDMA production and pulled its APA-01 licensing deal with Restora Neurosciences.
PharmAla Biotech has been granted a US process patent for enantioselective MDMA production and pulled its APA-01 licensing deal with Restora Neurosciences.
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science
Biologics

hVIVO acquires CRS Berlin to enter dermatology and women's health

hVIVO has bought the Berlin-based Phase I/II unit for a nominal upfront fee plus a revenue-linked earnout capped at roughly €6 million.
hVIVO has bought the Berlin-based Phase I/II unit for a nominal upfront fee plus a revenue-linked earnout capped at roughly €6 million.
The Biotech Times Editorial Team  · 
Diagnostics

Philips and Imricor launch combined cardiac iMR lab solution

The partners have commercialised a 1.5T MRI-based interventional lab for cardiac ablation, removing reliance on X-ray fluoroscopy in CE-marked markets.
The partners have commercialised a 1.5T MRI-based interventional lab for cardiac ablation, removing reliance on X-ray fluoroscopy in CE-marked markets.
The Biotech Times Editorial Team  · 
Regulatory Science

Nicox NCX 470 glaucoma NDA accepted with April 2027 PDUFA date

The FDA has set a 30 April 2027 review deadline for NCX 470, a nitric oxide-donating bimatoprost eye drop targeting open-angle glaucoma.
The FDA has set a 30 April 2027 review deadline for NCX 470, a nitric oxide-donating bimatoprost eye drop targeting open-angle glaucoma.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

Pfizer and BioNTech win FDA approval for XFG-adapted COMIRNATY

The companies' 2026-2027 mRNA COVID-19 vaccine, targeting the XFG variant, has been approved for high-risk adults and children aged five and over.
The companies' 2026-2027 mRNA COVID-19 vaccine, targeting the XFG variant, has been approved for high-risk adults and children aged five and over.
The Biotech Times Editorial Team  · 
Digital Health
Biotech

Big Digital Energy signs LOI for 17 MW AI campus in Texas

Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC
Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC
The Biotech Times Editorial Team  · 
Diagnostics

Femasys brings FemaSeed portfolio to UNC Health OB/GYN network

Femasys and UNC Health have partnered to offer in-office fertility diagnostics and intratubal insemination across the academic system's statewide OB/GYN locations.
Femasys and UNC Health have partnered to offer in-office fertility diagnostics and intratubal insemination across the academic system's statewide OB/GYN locations.
The Biotech Times Editorial Team  · 
Regulatory Science
Biologics

Mereo BioPharma licenses alvelestat to Sentynl in $475m-plus US deal

Mereo will receive up to $475m and tiered royalties if Sentynl exercises its US commercialisation option for the oral AATD-LD candidate.
Mereo will receive up to $475m and tiered royalties if Sentynl exercises its US commercialisation option for the oral AATD-LD candidate.
The Biotech Times Editorial Team  · 
Digital Health
Bioinformatics

Philips wins $33.7m ARPA-H award for AI robotic stroke care

Philips will work with Johns Hopkins and Boston University to develop remote and automated endovascular stroke procedures under the ARPA-H AIR programme.
Philips will work with Johns Hopkins and Boston University to develop remote and automated endovascular stroke procedures under the ARPA-H AIR programme.
The Biotech Times Editorial Team  · 
Biologics

Alvotech and Lotus sign $150m biosimilar deal for two biologics

Alvotech and Lotus Pharmaceutical will co-commercialise durvalumab and emicizumab biosimilars across the US and eight Asian markets.
Alvotech and Lotus Pharmaceutical will co-commercialise durvalumab and emicizumab biosimilars across the US and eight Asian markets.
The Biotech Times Editorial Team  · 

Nuwellis signs co-promotion deal with Atrility for AtriAmp device

Nuwellis will co-promote Atrility's FDA-cleared cardiac pacing monitor across 14 US states, with an option to become exclusive national distributor.
Nuwellis will co-promote Atrility's FDA-cleared cardiac pacing monitor across 14 US states, with an option to become exclusive national distributor.
The Biotech Times Editorial Team  · 
Biotech

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech

Taranis Capital, The Fintech Times and Co-Labs Global have partnered to accelerate FinTech, AI, RegTech and BioTech growth through capital, media and collaboration.

Strategic collaboration combines capital, media reach and collaborative services to cut through market noise and enable faster, safer and more resilient innovation for those who need it most.

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech  · 
Biologics

ADARx wins FDA Fast Track for onvuzosiran in hereditary angioedema

ADARx Pharmaceuticals has secured Fast Track designation for its siRNA candidate onvuzosiran, now in Phase 3 trials for HAE prophylaxis.
ADARx Pharmaceuticals has secured Fast Track designation for its siRNA candidate onvuzosiran, now in Phase 3 trials for HAE prophylaxis.
The Biotech Times Editorial Team  · 
Biologics

Alvotech and Lotus Pharmaceutical sign biosimilar deal worth up to $150m

Alvotech has licensed two biosimilar candidates to Lotus Pharmaceutical across the US and eight Asian markets, with milestone payments potentially reaching $150 million.
Alvotech has licensed two biosimilar candidates to Lotus Pharmaceutical across the US and eight Asian markets, with milestone payments potentially reaching $150 million.
The Biotech Times Editorial Team  · 
Biologics

VarmX enrols first patient in Phase 3 trial of FXa reversal agent

VarmX has begun enrolling patients in EquilibriX-S, its pivotal Phase 3 study of VMX-C001 for urgent surgery in patients on Factor Xa inhibitors.
VarmX has begun enrolling patients in EquilibriX-S, its pivotal Phase 3 study of VMX-C001 for urgent surgery in patients on Factor Xa inhibitors.
The Biotech Times Editorial Team  · 
Subscribe to Partnerships